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Abstract
Background: Molecular changes in multiple biological processes contribute to the development of chronic
neurodegeneration such as late onset Alzheimer’s disease (LOAD). To discover how these changes are reflected at
the level of gene expression, we used a subtractive transcription-based amplification of mRNA procedure to
identify novel genes that have altered expression levels in the brains of Alzheimer’s disease (AD) patients. Among
the genes altered in expression level in AD brains was a transcript encoding a novel protein, SDIM1, that contains
146 amino acids, including a typical signal peptide and two transmembrane domains. Here we examined its
biochemical properties and putative roles in neuroprotection/neurodegeneration.
Results: QRT-PCR analysis of additional AD and control post-mortem human brains showed that the SDIM1
transcript was indeed significantly down regulated in all AD brains. SDIM1 is more abundant in NT2 neurons than
astrocytes and present throughout the cytoplasm and neural processes, but not in the nuclei. In NT2 neurons, it is
highly responsive to stress conditions mimicking insults that may cause neurodegeneration in AD brains. For
example, SDIM1 was significantly down regulated 2 h after oxygen-glucose deprivation (OGD), though had
recovered 16 h later, and also appeared significantly up regulated compared to untreated NT2 neurons.
Overexpression of SDIM1 in neuro-progenitor cells improved cells’ ability to survive after injurious insults and its
downregulation accelerated cell death induced by OGD. Yeast two-hybrid screening and co-immunoprecipitation
approaches revealed, both in vitro and in vivo, an interaction between SDIM1 and DNAJB4, a heat shock protein
hsp40 homolog, recently known as an enhancer of apoptosis that also interacts with the mu opioid receptor in
human brain. Overexpression of DNAJB4 alone significantly reduced cell viability and SDIM1 co-overexpression was
capable of attenuating the cell death caused DNAJB4, suggesting that the binding of SDIM1 to DNAJB4 might
sequester DNAJB4, thus increasing cell viability.
Conclusion: Taken together, we have identified a small membrane protein, which is down regulated in AD brains
and neuronal cells exposed to injurious insults. Its ability to promote survival and its interaction with DNAJB4
suggest that it may play a very specific role in brain cell survival and/or receptor trafficking.
Background
Alzheimer disease (AD) is the most common neurode-
generative disorder, manifesting clinical symptoms of
cognitive impairment and dementia, which result from
progressive synaptic dysfunction, loss and neuronal cell
death. Pathologically, AD is characterized by the deposi-
tion of b-amyloid leading to the development of senile
plaques and hyperphosphorylated tau protein aggregates
within the cortical neurons, forming neurofibrillary tan-
gles (NFTs). Our current understanding of early onset
(familial) AD is derived primarily from studies on genes
or gene products identified in genetically determined
forms. These AD cases exhibit genetic linkage to muta-
tions in presenilin-1 (PS1), presenilin-2 (PS2) and b-
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these discoveries have been helpful in elucidating the
basic molecular pathogenesis of familial AD, they only
represent a relatively small fraction of the AD popula-
t i o n .T h el a r g em a j o r i t yo fc a s e sa r el a t eo n s e tA D
(LOAD), which are genetically heterogeneous and occur
sporadically. Several genetic risk factors have been
described for LOAD, notably an allelic polymorphism of
apolipoprotein E that affects the age of onset [2], but
the precise etiology of LOAD is poorly understood.
Alterations in multiple biological processes contribute
to the development of LOAD, some of which correlate
with cognitive impairment [3]. Well established brain
changes include excessive oxidative stress and insuffi-
cient antioxidant defenses, disrupted calcium homeosta-
sis, altered cholesterol synthesis and transport,
inappropriate hormonal and growth factor signaling,
chronic inflammation, aberrant re-entry of neurons into
the cell cycle and, especially, aberrant protein proces-
sing, folding and turnover, leading ultimately to senile
plaques and NFT formation [4]. Due to the vast extent
and complexity of these changes, global gene expression
profiling has been adopted as a discovery-based
approach to study this idiopathic and multifactorial dis-
ease. Although the discovery of concurrent changes in
AD brains cannot establish cause and effect, or separate
detrimental from compensatory effects, they can gener-
ate unique insights and testable hypotheses on processes
that may drive brain and cognitive dysfunction.
The most commonly used technology for the assess-
ment of gene expression changes in postmortem AD
brains is DNA microarray analysis [5-9]. This approach
has allowed relative quantitative assessment of thou-
sands of genes simultaneously, providing clues for new
candidate genes not previously associated with AD.
However, this method requires prior knowledge of gene
sequences and cannot be applied as a discovery tool for
novel transcripts. Furthermore, the expression levels of
low abundance genes cannot be readily assessed by
DNA microarray hybridization, as reliable results are
usually obtained only for genes that are expressed in
high or moderate levels. We have recently employed a
subtractive hybridization and RNA amplification method
to enrich and isolate rare and novel transcripts involved
in LOAD. Using this approach, we have isolated a num-
ber of novel transcripts that are differentially expressed
in the brains of AD patients [10]. Among these was a
novel sequence, SDIM1, that not only was down regu-
lated in AD brains, but was also very responsive to
stress conditions mimicking the injurious insults that
may cause neurodegeneration in AD brain.
In the present study, we demonstrate its biochemical
properties, tissue/cell type distribution, putative roles in
neuronal cells that are exposed to toxic insults causing
neurodegeneration, and have explored its relationship
with other key proteins in the brain.
Results
SDIM1 is a novel transmembrane protein down regulated
in AD brains
We have isolated a cDNA fragment by subtractive
hybridization using a pooled mRNA population from
AD brains as a “driver” and the first strand cDNAs from
a pooled age-matched control brains as a “tester” [10].
BLAST searches revealed that this fragment matches
with human cDNA FLJ26122 fis, clone SYN00634 on
chromosome 6 [GenBank AK129633, AL590482],
encoding an unnamed protein product [GenBank
BAC85201.1] of 146 amino acids (aa), with a calculated
molecular weight of ~13 kDa. The predicted primary
structure of this protein contained a typical N-terminal
s i g n a lp e p t i d eo f2 6a a .T h e r ea r et w op r i m a r yt r a n s -
membrane helices spanning amino acids 69 to 91, 97 to
119, respectively (Figure 1). No matching cDNAs from
rodents were found in the GenBank. Based on its struc-
ture and putative function determined by present study,
we named this gene as stress responsive DNAJB4 inter-
acting membrane protein 1 (SDIM1, HGNC approved).
Since the SDIM1 transcript was found in the subtracted
cDNA library containing genes potentially down regu-
lated in AD brains, we re-examined these changes by
qRT-PCR analysis (Figure 2A) of the RNA pools used to
construct the original AD and control cDNA libraries
[10]. These results were further confirmed by qRT-PCR
using 19 individual brain samples from a tissue bank
(Table 1). As shown in Figure 2B the SDIM1 transcript
level was significantly lower in most AD brains in com-
parison to the age-matched controls, suggesting that
SDIM1 transcript is indeed down regulated on AD
brains.
Expression pattern of SDIM1
Since the SDIM1 sequence exists in the GenBank as a
hypothetical protein, we set out to produce a specific
anti-SDIM1 antibody that can detect SDIM1 gene pro-
duct in tissues and cell lines. A polyclonal anti-SDIM1
peptide antiserum was generated in rabbits and further
purified by immumoaffinity methods. This anti-SDIM1
antibody faithfully recognized recombinant GST-SDIM1
fusion protein (Figure 3A, right lane) and detected two
bands from the protein extract from NT2 neurons
(Figure 3B). The lower band was located near 13-
15 kDa and the upper one appears at 26-27 kDa on
SDS-PAGE, which suggests that SDIM1 might form
dimeric aggregates under denaturing conditions. Modi-
fying the concentrations of DTT, b-mercaptoethanol,
and urea in the loading buffer, as well as changing the
boiling temperature from 100°C for 5 Min to 55°C for
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protein sequence contains two potential phosphorylation
sites and two O-linked glycosylation sites. There is no
N-linked glycosylation site on this protein. The size
increase resulted from these modifications do not seem
to match the size shift seen on the gel (Figure 3B).
Mono-ubiquitination may be a possibility for the upper
band that is recognized by anti-SDIM1 antibody. How-
ever, neither band was recognized by anti-ubiquitin anti-
body in western analysis experiments (Figure 3C).
Throughout the present study, we noticed that the
intensity of the upper band was always more pro-
nounced than the lower band, the upper band increased
as the lower band decreased and the lower band could
disappear completely if the same protein extracts had
been freeze-dried or been passed through multiple
freeze-thaw cycles prior to gel separation. This phenom-
enon led us to believe that the band shift was a result of
dimeric aggregation, instead of enzymatic modification,
which normally occurs under physiological conditions
in vivo. To prove that SDIM1 forms dimeric structure,
we performed co-immunoprecipitation experiments,
where cellular proteins from cells transfected with
pEGFP-N1 or pSDIM1-EGFP plasmids were mixed with
purified GST-SDIM1 fusion protein. Immunoprecipita-
tion was performed using anti-GST antibody and the
precipitated proteins were detected by anti-GST, anti-
EGFP and anti-SDIM1 antibodies. These experiments
showed that GST-SDIM1 formed dimmers (Figure 3D,
left panel, lane 4, also see Figure 3A) and it also formed
hetero-dimers with SDIM1-EGFP (Figure 3D, left panel,
lane 4 and middle panel, lane 4). SDIM1-EGFP also
formed self-dimmers as we observed a faint band in the
lane with total cellular proteins extracted from pSDIM1-
EGFP transfected cells (Figure 3D middle panel, lane 2).
The dimeric structures on the membrane shown in
figure 3D, middle panel, were further detected by anti-
SDIM1 antibody (Figure 3D right panel) and we did not
detect dimerization of EGFP with GST-SDIM1
(Figure 3D middle and right panels, lane 3). Western
analyses revealed ubiquitous expression of SDIM1 in
human and mouse tissues with higher levels in brain,
muscle, heart and reproductive organs (Figure 3E and
3F). SDIM1 dimer was the dominant form in the brain,
where the monomer was almost non-detectable. We
also observed small amounts of dimers in freshly
extracted cervix and muscle samples, where SDIM1 is
more abundant (Figure 3E and 3F). Western analysis of
proteins extracted from control and AD brain context
showed that the overall SDIM1 protein levels in AD
samples were indeed lower than those of controls
(Figure 3G). We only observed trace amounts of SDIM1
monomer in control samples, but it was not detectable
in the AD samples. Quantitative RT-PCR analysis
detected very low levels of SDIM1 transcript in undiffer-
entiated NT2 cells and NT2 derived astrocytes, but with
Figure 1 A schematic representation of the human SDIM1 protein structures. Structural motifs of the encoded protein were predicted by
ExPASy tools (http://bp.nuap.nagoya-u.ac.jp/sosui/sosui_submit.html).
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Page 3 of 16Figure 2 Expression pattern of SDIM1 transcript in control and AD human brains. A. Changes in mRNA levels of SDIM1 transcript in
control and AD brains were determined by qRT-PCR. The cDNA samples were prepared from pooled mRNA of 4 AD and 5 age-matched control
subjects. The value of the control sample was set at 100%. The percentage of the AD sample was calculated by 100x 2
-ΔCt, where ΔCt is the
cycle number difference between the AD sample and the control sample. The experiments were performed in triplicate. Asterisks indicate a
significant difference (p = 0.0014) B. Changes in mRNA levels of SDIM1 transcript in individual control and AD brains were determined by qRT-
PCR. The cDNA samples were prepared from mRNA of 9 AD and 10 age-matched control subjects. The qRT-PCR results were calculated against
the average result (control mean) of the control samples, set at 100%. Percentage of each sample was calculated by 100 × 2
-ΔCt, where ΔCt is
the cycle number difference between each sample and the control mean. The experiments were performed in triplicate.
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Page 4 of 16significantly increased expression in NT2 neurons (Fig-
ure 4A). Its abundance in neurons was further con-
firmed by Western analysis using anti-SDIM1 antibody
(Figure 4B). In these cells the dimer was also seen as
the dominant form of SDIM1. To examine the cellular
localization of SDIM1, we double stained mouse primary
neuronal cultures with SDIM1 and MAP2 antibodies.
SDIM1 protein is located mainly in the cytoplasm and
distributed throughout the neuro-processes (Figure 4C
a). Although SDIM1 has similar cellular distribution as
that of MAP2 in mature neurons, it is not co-localized
with MAP2 in the processes (Figure 4C d). Consistent
with the Western analysis results shown in 4B, in the
immature neurons, where there was no MAP2 immu-
noreactivity, we observed less SDIM1 staining than in
mature neurons (Figure 4C arrowheads), suggesting that
SDIM1 is more abundant in neuronal cells in the brain.
SDIM1 is highly responsive to stress conditions mimicking
injurious insults
We analyzed the SDIM1 expression level in post-mitotic
NT2 neurons subjected to oxygen and glucose deprivation
(OGD), which has been previously reported to trigger neu-
ronal apoptosis [11]. Here, initially the cells were subjected
to 2 h OGD treatment, during which 10-15% of cells lost
viability, followed by a 16 h recovery period, at the end of
which cell death reached 35-40%. The SDIM1 mRNA was
significantly down regulated after the OGD treatment
(Figure 5A), but became significantly up regulated 16 h
after recovery. The changes in protein level, as verified by
Western blot analysis, followed the same pattern (Figure
5B). Cultured mouse primary neurons responded to OGD
treatment in the same fashion as that of the NT2 neurons
(Figure 5C). Immunostaining of these OGD treated pri-
mary neurons showed that they had decreased immunor-
eactivity to anti-SDIM1 antibody and the cells appeared to
have retracted their processes (Figure 5D). However, 16 h
after re-oxygenation, the surviving cells had much brighter
SDIM1 staining and normal neural processes. Dead or
dying cells contained much less SDIM1 protein (data not
shown). Taken together, our results indicated that SDIM1
had a bi-phasic response to cell death inducing injuries - a
down regulation in response to the initial treatment, fol-
lowed by significant up regulation in surviving cells.
Overexpression of SDIM1 protected cells from injurious
insults and its downregulation accelerated cell death
caused by OGD in neuronal progenitor cells
To better understand the role of SDIM1 in neuroprotec-
tion we examined the effects of gene over-expression in
the N2a cell line. We cloned the coding region of
SDIM1 into a mammalian expression vector, pEGFP-
N1, with a stop codon inserted between the end of the
SDIM1 and the beginning of EGFP. As a result, a faint
green fluorescent signal was observed in the cells trans-
fected with the plasmid construct, but the SDIM1 pro-
tein was free to perform its routine function without the
possible interference of the EGFP. A time course
Table 1 Description of brain samples used for qRT-PCR analysis of SDIM1
Patient Sex Age Postmortem Pathology
Control 1 Male 67 4.5 hours Normal
Control 2 Female 88 4-8 hours Normal
Control 3 Male 64 6 hours Normal
Control 4 Female N/A 4-8 hours Normal
Control 5 Male N/A 4-8 hours Normal
Control 6 Male 89 9 hours Normal
Control 7 Male 64 8 hours Normal
Control 8 Male 63 8 hours Normal
Control 9 Male 80 9.5 hours Normal
Control 10 Male 95 11 hours Normal
AD 1 Female N/A 4-8 hours AD, Dementia
AD 2 Male N/A 4-8 hours Moderate senile changes of AD type, dementia
AD 3 Male N/A 6 hours Subdural hematomas, senile changes of AD type
AD 4 Male N/A 4-8 hours Moderate senile changes of AD type, dementia
AD 5 Female 93 8 hours Probable AD, according to CERAD, CVD cerebrum, right infarct old
AD 6 Female 84 8 hours Probable AD, according to CERAD
AD 7 Female 85 7.5 hours Probable AD, according to CERAD
AD 8 Male 77 6 hours Senile dementia of AD type
AD 9 Female 86 7 hour CERAD classification 2, definite AD
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Page 5 of 16Figure 3 Expression levels of SDIM1 protein in human and mouse tissues. A. Anti-SDIM1 antibody was tested on recombinant GST-SDIM1
fusion protein (right lane). Left lane-Coomassie Blue stained GST-SDIM1. B. Anti-SDIM1 antibody detected SDIM1 in proteins extracted from NT2
neurons. C. SDIM1 protein from mouse brain (lane 1), muscle (lane 2) and HEK-293 cells over-expressing SDIM1 (lane 3) was detected with anti-
SDIM1 (left panel) or anti-ubiquitin (right panel) antibody. Lane 4-purified human ubiquitin. D. GST-SDIM1 protein was mixed with proteins from
HEK-293 cells transfected with pEGFP-N1 or pSDIM1-EGFP and immunoprecipitated with anti-GST antibody. The presence of monomeric and
dimeric GST-SDIM1, GST-SDIM/SDIM1-EGFP or SDIM1-EGFP was detected by anti-GST (left panel) or anti-EGFP (middle panel) antibody. The
second blot was stripped and probed with anti-SDIM1 anti-body (right panel). Lane1-total proteins from pEGFP-N1 transfected cells, lane 2-total
proteins from pSDIM1-EGFP transfected cells, lane 3-mixture of GST-SDIM1 and protein from pEGFP-N1 transfected cells immunoprecipitated
with anti-GST antibody, lane 4-mixture of GST-SDIM1 and protein from pSDIM1-EGFP transfected cells immunoprecipitated with anti-GST
antibody, lane 5-mock immunoprecipitation without anti-GST antibody. E. The expression levels of SDIM1 protein in human tissues were
detected by Western analysis with anti-SDIM1 antibody. A representative blot from each lot was tested by the vendor with anti-GAPDH
antibody. Lane B-Brain, lane K-Kidney, lane L-Lung, lane S-Spleen, lane I-Small Intestine, lane U-Uterus, lane C-Cervix, lane P-Placenta. F. SDIM1
protein in mouse tissues was detected by Western analysis with anti-SDIM1 antibody. The striped membrane was re-blotted with anti-b-actin
and anti-GAPDH antibodies. Lane B-Brain, lane I-Intestine, lane C-Cervix, lane Li-Liver, lane M-Muscle, lane H-Heart, lane L-Lung, lane K-Kidney,
lane S-Spleen. G. SDIM1 protein in control and AD human brains were detected by Western analysis with anti-SDIM1 antibody.
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Page 6 of 16Figure 4 Cell type specific expression and cellular localization of SDIM1. A. Changes in mRNA levels of SDIM1 during RA-induced
differentiation of NT2 cells were determined by qRT-PCR. The samples were measured against the cDNA of undifferentiated NT2 cells as a
control, set at 100%. Percentage of each sample was calculated by 100 × p 2
-ΔCt, where ΔCt is the cycle number difference between test sample
and the control sample. undiff - undifferentiated NT2 cells (control), NT2A - NT2 astrocytes, NT2N - NT2 neurons. The experiments were
performed in triplicate. Asterisks indicate a significant difference (p-value = 0.00024 for Undiff and NT2A; p-value = 0.0027 for Undiff and NT2N;
p-value = 0.0029 for NT2A and NT2N). B. Changes in SDIM1 protein levels were determined by Western blotting with anti-SDIM1 antibody using
100 μg/lane of total cellular protein. The Western blotting of b-actin was shown as loading control. C. Subcellular localization of SDIM1. Mouse
primary cortical neurons were fixed and stained with anti-SDIM1 and anti-MAP2 antibodies. Staining with secondary anti-body alone was also
performed as a negative control (image not show). FITC-conjugated anti-rabbit IgG (for SDIM1) and rhodomine-conjugated anti-mouse IgG (for
MAP2) were used to detect the specific immunostaining. The nuclei were stained with DAPI and viewed with a Zeiss Axiovert 200 M
fluorescence microscope. Arrowheads indicate glial cells or inmature neurons. Scale bar in c = 50 μM.
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point, when SDIM1 protein reached the plateau. While
there was a gradual increase in protein level from 16 h
to 21 h after transfection, we were surprised to discover
that SDIM1 protein level deceased quickly after it
reached the plateau at 21 h. Although the mRNA level
remained much higher than the untransfected control,
protein levels dropped to the same level 24 h after
transfection (Figure 6A and 6B). This result suggests
that there is a degradation mechanism controlling the
protein level of SDIM1. Therefore over-expression of
SDIM1 for 21 h was chosen for subsequent over-
Figure 5 Bi-phasic response of SDIM1 in NT2 and mouse primary neurons treated with cell death-inducing stress. A. Changes in mRNA
levels of SDIM1 in NT2 neurons treated with OGD and OGD with 16 h recovery were determined by qRT-PCR. The samples were measured
against the cDNA of untreated NT2 neurons, set at 100%. Percentage of each treated sample was calculated by 100 × 2
-ΔCt, where ΔCt is the
cycle number difference between treated sample and the control sample. The experiments were performed in triplicate. Asterisks indicate a
significant difference (p-value = 6.25E-05 for control and 2hOGD; p-value = 0.0032 for control and 2hOGD + 16hR; p-value = 0.0023 for 2hOGD
and 2hOGD + 16hR). B. a. Changes in SDIM1 protein levels in NT2 neurons treated with OGD and OGD plus 16 h recovery were determined by
Western blotting with anti-SDIM1 antibody. Band intensity was measured using ImageJ and the level of SDIM1 was normalized against the level
of b-actin and plotted in b. Asterisk indicates a significant difference (r < 0.005; t-test). C. a. Changes in SDIM1 protein levels in mouse primary
neurons treated with OGD and OGD plus 16 h recovery were determined by Western blotting with anti-SDIM1 antibody. Band intensity was
measured using ImageJ and the level of SDIM1 was normalized against the level of b-actin and plotted in b. Asterisk indicates a significant
difference (r < 0.005; t-test). D. Changes of immunoreactivity of SDIM1 in primary neurons treated with OGD and OGD plus 16 h recovery. Cells
were stained with anti-SDIM1 antibody. Cy3-conjugated anti-rabbit IgG was used to detect the specific immunostaining. The stained cells were
viewed with a Zeiss Axiovert 200 M fluorescence microscope. Scale bar = 50 μM.
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SDIM1 was over expressed in N2a cells without any cell
death inducer, we did not observe any changes in cell
viability. However, when the transfected cells were chal-
lenged by OGD treatment, we observed a significant
decrease in cell death when compared with cell popula-
tions transfected with pEGFP-N1 vector control (Figure
6C). Next, we down regulated the endogenous SDIM1
in NT2 cells using a mixture of four siRNAs targeting
human SDIM1. Most of the SDIM1 transcript and
protein were knocked down 24 h after the siRNA trans-
fection (Figure 6D). The transfected cells (after 24 h)
were subjected to 6 h OGD treatment plus 16 h re-
oxygenation and examined for cell viability (Figure 6E).
Figure 6 Cellular levels of SDIM1 modulate the rates of cell death. N2a or ERK293 cells were transiently transfected with pSDIM1*EGFP
plasmid. NT2 cells were transfected with synthetic siRNAs. Cells were collected for total RNA and protein extractions 16-24 h after transfections.
Trypan Blue exclusion assay was performed 21 or 24 h after transfection or 16 h after a 6 h OGD treatment of the transfected samples. Over
expression of SDIM1 mRNA was assessed by RT-PCR (A) and Western analysis (B). Lane C - negative PCR control, lane V- mock transfection with
pEGFP-N1 vector, lane 16 h - transfection with pSDIM1*EGFP plasmid for 16 h, lane 18 h - transfection with pSDIM1*EGFP plasmid for 18 h, lane
21 h - transfection with pSDIM1*EGFP plasmid for 21 h, lane 24 h - transfection with pSDIM1*EGFP plasmid for 24 h. C. Percentage of cell death
after pSDIM1*EGFP transfection for 21 h. Bars represent the percentage of cell death in the population (mean ± SEM from 3 independent
experiments performed in duplicate). Asterisk indicates a significant difference (p-value = 0.0096). D. Assessment of the siRNA silencing efficiency.
RNA and protein samples were collected 24 after transfection with siRNAs. Down regulation of SDIM1 was analyzed by RT-PCR and Western
blotting. E. Percentage of cell death 24 h after siRNA transfection, with or without OGD treatment. Bars represent the percentage of cell death in
the population (mean ± SEM from 3 independent experiments performed in duplicate). Asterisks indicate a significant difference (p-value =
0.001). Ctrl24 - 24 h after transfection with negative control siRNAs, siRNA24 - 24 h after transfection with SDIM1 pool siRNAs, Ctrl24-OGD - 24 h
after transfection with negative control siRNAs plus OGD treatment, siRNA24-OGD - 24 h after transfection with pool SDIM1 siRNAs plus OGD
treatment.
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alone, no significant increase in cell death percentage
was observed. However, down-regulation of the endo-
genous SDIM1 followed by OGD treatment significantly
increased the percentage of cell death caused by OGD
treatment.
SDIM1 interacts with a DnaJ-like heat shock protein
To further identify the roles of SDIM1 in neuronal cell
death or survival we performed yeast two-hybrid screen-
ing to identify its potential interacting proteins in
human brain. Yeast strain AH109 harboring the two-
hybrid construct (pGBKT7-SDIM1) expressing full
length human SDIM1 was used to screen a human
brain expression cDNA library. Among 4 clones that
displayed Ade/His prototype and b-galactosidase activ-
ity, one sequence was found to encode human DnaJ-like
heat shock protein (DNAJB4), also known as HLJ1. The
interaction between these two proteins was reproducibly
reconstructed in the yeast two-hybrid system and it
passed all required tests (Figure 7A). Because the endo-
genous levels of SDIM1 and DNAJB4 were very low in
most cell lines, in order to establish the interaction of
these two proteins in vivo, we co-transfected flag-tagged
DNAJB4 and EGFP tagged SDIM1 plasmids into HEK
293 cells. The transfected cells were harvested and the
protein extracts were immmunoprecipitated with anti-
flag antibody. The precipitated protein complex was
boiled and separated by SDS/PAGE. The blot was first
probed with anti-flag antibody to ensure that DNAJB4
protein was successfully precipitated by the anti-flag
antibody (Figure 7B). The same protein samples were
subsequently probed with anti-SDIM1 or anti-EGFP
antibody for SDIM1 (Figure 7C). Our results confirmed
the interaction detected through the yeast two-hybrid
assay. Next, we examined the sub-cellular localization of
these proteins by double staining of mouse primary
neurons with anti SDIM1 and DNAJB4 antibodies.
Co-localization of these proteins was detected in the
cytoplasm and neuroprocesses (Figure 7D). Decreased
amounts of SDIM1 were detected in apoptotic cells;
only trace amounts of DNAJB4 was detected in these
dying cells (Figure 7D, b and 7c, arrowhead). This result
is in agreement with the physical interaction detected in
the yeast two-hybrid and co-immunoprecipitation
assays.
SDIM1 attenuates cell death induced by DNAJB4
overexpression
To understand the biological significance of the interac-
tion between SDIM1 and DNAJB4, we first examined
the expression patterns of DNAJB4 in AD brains and in
cultured NT2 and primary neurons. We did not
detected significant changes of DNAJB4 transcript in
AD brains by qRT-PCR (data not show). We detected a
bi-phasic change of DNAJB4 protein in NT2 and mouse
primary neurons after OGD treatment and re-oxygena-
tion similar to that observed with SDIM1 (Figure. 8A
and 8B). However, we did not observe an increased
expression of DNAJB4 in surviving cells in these neuro-
nal cultures 16 h after re-oxygenation. The DNAJB4
level in the recovering cells (after re-oxygenation) was
always lower than that of untreated cells. These data
suggested that DNAJB4 may not have a protective func-
tion similar to SDIM1 in surviving cells. To test this
hypothesis, we transiently over-expressed DNAJB4 in
N2a cells with a pCMV-DNAJB4-Tag1 plasmid for 21 h.
Surprisingly, over-expression of DNAJB4 triggered sig-
nificant amounts of cell death as compared with mock
transfection of empty vector, and co-transfection of
DNAJB4 with SDIM1 attenuated cell death caused by
DNAJNB4 over-expression (Figure 8C). The subsequent
challenge of these transfected cells with OGD caused
additional loss of cells in all samples, but the prior
observations were reproduced in that SDIM1 over-
expression reduced cell death caused by both OGD
treatment and DNAJB4 over-expression (Figure 8D).
The over-expression of DNAJB4 and SDIM1 proteins in
the transfected cells were confirmed by Western ana-
lyses (Figure 8E). To investigate whether DNAJB4
induced cell death is through SDIM1 degradation
mediated by DNAJB4; we performed a time course
experiment of DNAJB4 over-expression and assessed
the levels of endogenous SDIM1. While we detected a
consistent increase of DNAJB4 levels at 16, 18, 21 and
24 hour time points due to the transfection of pCMV-
DNAJB4-tag1 plasmid, we did not observe a decrease
of SDIM1 protein at any time point (data not show);
instead, we found a significant increased of SDIM
mRNA and protein levels 24 h after DNAJB4 over-
expression (Figure 8F and 8G). Next, we down regu-
lated the endogenous DNAJB4 alone or SDIM1 and
DNAJB4 simultaneously using synthetic siRNAs target-
ing human DNAJB4 and/or SDIM1 in human NT2
cells. The proteins were knocked down 24 h after
siRNA transfection (Figure 8H). The transfected cells
were then subjected to 6 h OGD treatment and 16 h
re-oxygenation in a normal culture chamber and
examined for cell viability (Figure 8I). The results
showed that down regulation of DNAJB4 significantly
reduced the percentage of cell death caused by OGD
treatment. In contrast, down regulation of SDIM1
significantly increased cell death percentage and when
both proteins were knocked down the cell death
percentage returned to levels similar to control cells
( F i g u r s .6 E ,8 I ) ,s u g g e s t i n gt h a te n d o g e n o u sD N A J B 4
can promote cell death triggered by OGD and endo-
genous SDIM1 promotes cell survival.
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Page 10 of 16Figure 7 SDIM1 physically interacts with DNAJB4. A. Interaction between SDIM1 and DNAJB4 in yeast two-hybrid system. Empty or SDIM1
containing pGBKT7 bait vector and empty or DNAJB4 containing pACT2 library vector were co-transformed into yeast host cells AH109 and
plated onto SD/-Trp -Leu -Ade -His + X-a-gal plate. a - a negative test of empty bait vector and DNAJB4, b - a negative test of SDIM1 bait plus
empty library vector, c - a positive test showing the interaction between SDIM1 and DNAJB4, d - a standard positive control showing interaction
between p53 and T antigen. B. Total cellular proteins were extracted from HEK-293 cells co-transfected with flag-tagged DNAJB4 and EGFP-
tagged SDIM1 constructs and immunoprecipitated with anti-flag antibody. The presence of DNAJB4 in the complex was detected by anti-flag
antibody. Lane1 - total cellular proteins extracted from untransfected cells, lane 2 - total cellular proteins extracted from cells co-transfected with
pCMV-DNAJB4-Tag1 and pSDIM1-EGFP, lane 3 - mock immunoprecipitation without primary anti-flag antibody, lane 4 - proteins
immunoprecipitated with anti-flag antibody. C. The presence of SDIM1 in the complex, shown in B, was revealed by Western blotting with anti-
SDIM1 antibody. Lane assignment is the same as those in B. D. Co-localization of SDIM1 and DNAJB4. Mouse primary neurons were fixed and
stained with anti-SDIM1 anti-DNAJB4 antibodies. FITC-conjugated anti-rabbit IgG (for SDIM1) and rhodomine-conjugated anti-mouse IgG
(DNAJB4) were used to detect the specific immunostaining. The nuclei were stained with DAPI and viewed with a Zeiss Axiovert 200 M
fluorescence microscope. a. DAPI stained nuclei. b. Anti-SDIM1 staining. c. Anti-DNAJB4 staining. d. a, b and c overlay. Arrowheads indicate an
apoptotic cell. Scale bar in a = 50 μM.
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We have isolated a novel neuron-enriched protein,
SDIM1, which is down regulated in AD brain tissues.
Further study of its expression in NT2 cell model and in
mouse primary neurons revealed that this gene was
barely detectable in undifferentiated NT2 cells, and is
much more abundant in differentiated neurons than
astrocytes. Treatments of neuronal cells with OGD and
OGD plus 16 h recovery triggered a bi-phasic response of
SDIM1 transcript and protein. SDIM1 is down regulated
2ha f t e rO G D ,b u tb e c a m eh i g h l yu p - r e g u l a t e d1 6h
after re-oxygenation, in surviving neurons. Furthermore,
over-expression of SDIM1 in N2a cells protected the
cells from apoptosis caused by OGD insults. Conversely,
down-regulation of SDIM1 by siRNA alone did not trig-
ger cell death, whereas down-regulation of SDIM1 fol-
lowed by OGD treatment of the cells caused accelerated
cell death. These results suggest that SDIM1 is capable of
promoting cell survival and this protective function is
induced by signals triggered by stress conditions.
Although analysis of human and mouse tissues indi-
cated that SDIM1 is relatively abundant in muscle, heart
and reproductive organs, suggesting that this protein
may have a basic housekeeping function under normal
Figure 8 SDIM1 attenuates cell death induced by DNAJB4 overexpression. Changes in DNAJB4 protein levels in NT2 neurons (A)a n d
mouse primary neurons (B) treated with OGD and OGD plus 16 h recovery were determined by Western blotting with anti-DNAJB4 antibody.
C. Percentage of cell death after DNAJB4 overexpression alone or co-overexpression with SDIM1 in N2a cells. Cell death percentage was assessed
21 h after transfection. Bars represent the percentage of cell death in the population (mean ± SEM from 3 independent experiments performed
in duplicate). Asterisk indicates a significant difference (p-value = 0.0016 for pCMV-Tag1 and DNAJB4; p-value = 0.0022 for DNAJB4 and DNAJB4/
SDIM1). D. Percentage of cell death of the transfected cells after OGD treatment. The single or double transfected cells shown in C were treated
with OGD for 6 h and allowed to recover for 16 h. The cell death assay was performed as described for C. (p-value = 0.0033 for pCMV-Tag1 and
DNAJB4; p-value = 0.0027 for pEGFP-N1 and SDIM1; p-value = 0.057 for DNAJB4 and DNAJB4/SDIM1). E. Assessment of gene overexpression
efficiency. Protein samples were collected 21 h after transfection. Overexpression of SDIM1 and DNAJB4 proteins was analyzed by Western
blotting. F. RT-PCR analysis of RNA levels of DNAJB4 and SDIM1 in N2a cells transfected with pCMV-DNAJB4 or control vector pCMV-tag1.
G. Western analysis of protein levels of the same samples shown in F. H. Assessment of siRNA silencing efficiency. NT2 cells were transfected or
double transfected with synthetic siRNAs targeted for DNAJB4 and/or SDIM1. Cells were collected for protein extractions 24 h after transfection.
I. Percentage of cell death 24 h after siRNA transfection followed by OGD treatment. (p-value = 0.032 for DNAJB4 and control; p-value = 0.029
for DNAJB4 and DNAJB4/SDIM1; p-value = 0.023 for control and SDIM1).
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Page 12 of 16physiological conditions, it is the down regulation in AD
brains that links SDIM1 to diseased conditions. SDIM1
transcript level is significantly lower in the cortex of AD
patients than that of age matched controls. In our cell
systems treated with injurious insults, SDIM1 is also
down regulated and only becomes up regulated in sur-
viving cells when given a recovery period. These results
indicate that the surrounding microenvironment of the
AD brain presents a constant stressed condition for
brain cells. Neuroinflammation, oxidative stress, ische-
mia and Ab deposition could all contribute to the crea-
tion of this harmful environment. Based on the siRNA
knock down experiments, down regulation of SDIM1
alone is not enough to kill cells. However, when down-
regulation of SDIM1 in the cells combined with injur-
ious insults caused increased amounts of cell death,
suggesting that a decreased level of SDIM1 in the
microenvironment of AD brains may likely cause neuro-
nal cell death.
Through yeast two hybrid and co-immunoprecipitation
assays we have discovered that SDIM1 interacts with
DNAJB4, a member of DNAJ like heat shock protein 40.
DNAJ/HSP40 proteins have been characterized as co-
chaperones involved in the regulation of HSP70 chaper-
one activities [12]. DNAJB4 has been recently identified
as a novel tumor suppressor of non-small-cell lung can-
cer (NSCLC) that can inhibit cancer cell cycle progres-
sion, proliferation, invasion and tumorigenesis. DNAJB4
expression was lower in tumors than adjacent normal tis-
sues and patients with high DNAJB4 expression tumors
had reduced cancer recurrence and longer survival than
those with lower expressing tumors [13]. Studies on its
regulatory mechanism revealed that DNAJB4 is transcrip-
tionally up regulated via enhancer activator protein-1
(AP-1) binding to promoter Yin Yang-1 (YY1) and the
co-activator, p300 [14,15]. Further investigations on the
mechanism of action of DNAJB4 on tumor progression,
particularly on its role in apoptosis of lung cancer cells
exposed to UV stress, has indicated that DNAJB4 pro-
motes UV induced apoptosis through JNK and caspase-3
activation in NSCLC cell line. DNAJB4 is a substrate of
caspase-3 and this cleavage of DNAJB4 by caspase-3 is
required for UV induced apoptosis in CL1-5 cells stably
overexpressing DNAJB4. Consequently, DNAJB4 is
reduced in UV exposed cells, and almost completely
depleted by the late stage of apoptosis [16]. The results
on the role of DNAJB4 in apoptosis obtained in the pre-
sent study is, in principle, consistent with those obtained
from NSCLC cell lines, in that over-expression of
DNAJB4 in N2a cells promotes apoptosis. Silencing
DNAJB4 decreases apoptosis induced by OGD (Figurs.
8C, 8I,). The difference is that transient over-expression
of DNAJB4 alone in N2a cells can trigger apoptosis with-
out any apoptotic inducer. This discrepancy is likely due
to the fact that the NSCLC cell over expressing DNAJB4
is a cell line that had passed through a selection proce-
dure for stable, forced-expression of exogenous DNAJB4.
Many cells that initially over-express DNAJB4 would
undergo apoptosis and might not survive long enough to
form stably transfected clones. Further studies are
required to identify whether the underlying molecular
mechanism of DNAJB4 triggered cell death in neuro-pro-
genitor cells is similar to that in NSCLC cells.
DNAJB4 is identified in the present study as a protein
that interacts with a novel neuron-enriched protein
SDIM1 that is down regulated in AD brains. However,
we did not detect significant changes of DNAJB4 in AD
brains. The fact that DNAJB4 protein is quickly depleted
in apoptotic neurons and in NSCLC makes it difficult to
quantitate whether there exists an initial up regulation
of DNAJB4 which triggers the cascade of neurodegen-
eration in AD brains. The decreased amounts of
DNAJB4 in cultured NT2 or primary neurons either
during OGD treatment or after the recovery period is
also likely due to the depletion of this protein in apop-
totic cells. In these cell models, SDIM1 is highly respon-
sive to OGD treatment. It’su pr e g u l a t i o ni nt h e
surviving cell population is highly pronounced, implying
a protective function. Over-expression of DNAJB4 trig-
gered an increase of endogenous SDIM1 suggesting that
DNAJB4 induced cell death is not due to SDIM1 degra-
dation mediated by DNAJB4; instead, this over-expres-
sion can trigger SDIM1 up-regulation, thus protect cells
from DNAJB4 induced apoptosis (Figure 8F and 8G).
This protective function appears to be independent of
OGD treatment, because over-expression of SDIM1
attenuated apoptosis caused by DNAJB4 over-expression
without any OGD treatment (Figure 8C). On the other
hand, knocking down SDIM1 by siRNA silencing
increases cell death induced by OGD (Figure 6E), indi-
cating that SDIM1 also protects cells from apoptosis
caused by OGD. Taken together, our data suggest that
SDIM1 is a novel protein that possesses protective func-
tion against stress induced cell death.
It has been reported that DNAJB4 interacts with the
carboxyl tail of human mu opioid receptor in the cell
membrane [17]. While the functional relevance of this
interaction still remains elusive, since DNAJB4 interacts
with HSP70, and the latter is involved in synaptic trans-
mission and regulation, it was speculated that DNAJB4
might work in concert with other HSP proteins to play
a role in receptor trafficking.
Conclusions
We have isolated a novel neuron-enriched protein,
SDIM1, which is down regulated in AD brains. Further
study of its function in neuronal cell models indicates
that this protein is protective of neuro-progenitor cells
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with DNAJB4, which is an apoptotic enhancer in
NSCLC cells, and its ability to attenuate DNAJB4
mediated apoptosis suggest an anti-apoptotic function of
SDIM1. However, further studies are necessary to
understand the role of DNAJB4 in brain tissues, espe-
cially in the context of AD, and the protective mechan-
ism of SDIM1 under stressed conditions in human
brain.
Methods
Cell culture and oxygen-glucose deprivation (OGD)
treatment
Human embryonal teratocarcinoma Atera2/D1 (NT2)
cells (Stratagene, La Jolla, CA), mouse Neuro-2a (N2a)
neuroblastoma cells (ATCC CCL-131) and human HEK
293 cells [18] were cultured in Dulbecco’sm o d i f i e d
Eagle’s medium (Invitrogen, Bethesda, MD) supplemen-
ted with 10% fetal calf serum (GCS, Wisent, Inc. St.
Bruno, PQ). NT2 cells were differentiated into neurons
and astrocytes with all trans-retinoic acid (RA, Sigma,
Oakville, ON) according to the method of Pleasure and
Lee [19] as described previously [20]. Mouse primary
cortical neurons were prepared from embryonic E15-16
CD1 mice and cultured in neurobasal media for 5-14
days as previously described [21].
For OGD treatment, NT2 neurons and mouse primary
neurons were washed once with glucose-free DMEM,
and incubated in glucose-free DMEM with 10% FBS for
2 h in a hypoxic chamber (Forma 1025 Anaerobic
Chamber; ThermoForma, Marietta, OH, USA). At the
end of the OGD treatment, cells were removed from the
chamber and returned to the incubator for 16 h. The
same OGD treatment was performed with undifferen-
tiated NT2 and N2a cells except the incubation in OGD
conditions was increased to 6 h due to their resistance
to OGD treatment. Cell viability for all cell lines was
assessed by the Trypan Blue (Sigma, Oakville, ON)
exclusion assay. In this procedure, all floating cells were
collected from culture media and washing buffer, and
then combined with the trypsinized cells. Cells were
incubated in the Trypan Blue dye for 5 min. Labelled
cells were counted using a hemocytometer.
RNA extraction, real time quantitative RT-PCR (qRT-PCR)
and semi-quantitative RT-RCR
RNA extraction, first strand cDNA synthesis, and qRT-
PCR analysis were performed as described previously
[22]. RNA pools extracted from frontal cortex of post-
mortem human brain samples described previously [23]
were used for subtractive hybridization and qRT-PCR.
Additional brain samples were obtained from the Human
Brain and Spinal Fluid Resource Center ([24], VAMC,
Los Angeles, CA), which is sponsored by NINDS/NIMN,
National Multiple Sclerosis Society, VA Greater Los
Angeles Healthcare System, and Veterans Health Services
and Research Administration, Department of Veteran
Affairs. To detect the expression level of the SDIM1 tran-
script in brain tissue and cultured cells, equal amounts of
cDNA (2 ng each) were used with the primers: SDIM1F
5’ GGGCCATGAACACATCACTTG 3’ and SDIM1R 5’
TCAGGTCAAAGTTGGCAATGAA 3’.T h eD N A J B 4
transcript was detect by using the primers: DNAJB4F 5’
TCTCAAACAAGACCCTCCCA 3’ and DNAJB4R 5’
ATGGCAGCCCATATCCAATA 3’. PCR was performed
using a ABI 7500 FAST Real Time PCR system and
reagents according to the manufacturer’s instructions.
The primers used for semi-quantitative RT-PCR for
SDIM1 are: F 5’ TCGGTGGGAAGACTGCTTAT 3’ and
R5 ’ CGTCTGTCCTGTGACATGGT 3’;f o rD N A J B 4
are: F 5’ TGGTTGTACCAAACGGATGA 3’ and R 5’
ATGGCAGCCCATATCCAATA 3’.
Plasmids, transient transfections and staining
Human cDNA encoding the mature (without the signal
peptide) SDIM1 protein was cloned into the pGEX -3X
vector (GE Healthcare, Baie d’Urfe Quebec) for GST-
SDIM1 fusion protein production. The first amino acid
after the signal peptide (position 27) was mutated from
“C” to “A” in order to increase the solubility of the
r e c o m b i n a n tS D I M 1p r o t e i ni nE .c o l i .H u m a nc D N A
encoding full length SDIM1 protein was cloned in the
pEGFP-N1 vector (Clontech, Palo Alto, CA, USA) with
or without a stop codon added between the C-terminus
of SDIM1 and the EGFP sequence (Invitrogen, Burling-
ton, ON) to produce pSDIM1*EGFP, pSDIM1-EGFP
respectively. The coding region of the human DNAJB4
cDNA was cloned into the pCMV-Tag1 vector to create
a pCMV-DNAJB4-Tag1 construct.
For overexpression analysis, N2a cells were plated in 6-
well plates at a density of 0.5 × 10
6 cells/well, 24 h before
transfection. Cells were transfected with 5 μgp C M V -
DNAJB4-Tag1 plasmid or pSDIM1*EGFP plasmid and 15
μl lipofectAmine 2000 reagent, or co-transfected with 2.5
μg each of the pSDIM1*EGFP and pCMV-DNAJB4-Tag1
plasmids plus 15 μl lipofectAmine 2000 reagent. Cells
were collected for Trypan Blue exclusion assay as well as
total RNA and protein extraction 16-24 h after transfec-
tion; or treated with OGD for 6 h plus 16 h recovery
prior to Trypan blue assay or total RNA and protein
extraction. For siRNA silencing, the siRNAs were pur-
chased from GenePgarma (Shanghai GenePgarma Co,
Ltd, Shanghai, PRC). Undifferentiated NT2 cells were
plated in 12-well plates at a density of 0.25 × 10
6 cells/
well, 24 h before transfection. Cell were transfected with
100 μM mixed human SDIM1 siRNAs containing a pool
of two sequences: 5’ UUAAACAGAGAUAUAAGUC 3’
and 5’ UUUAAUAGACCACAAACUC 3’ and/or 100 μM
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sequences: 5’ UUGGAUAGUCUAGCACUUC 3’,5 ’
UUUCUUCAGAAUCUCUACC 3’ and 5’ UUUCGA-
GAAAUCUUCAUCC 3’ using Dharmafect1 transfection
reagent according the manufacturer’s instructions (Dhar-
macon, Thermo Fisher Scientific, Inc). Cells were sub-
jected to 6 h OGD treatment 24 h after transfection and
collected for Trypan Blue exclusion assay 16 h after re-
oxygenation. For co-immunoprecipitation analysis, HEK
293 cells were plated in 10 cm plates at a density of 2 ×
10
6 cells /plate, 24 h before transfection. Cells were trans-
fected with 15 μg of pEGFPN1 or pSDIM1-EGFP alone,
or co-transfected with 7.5 μg each of pSDIM1-EGFP and
pCMV-DNAJB4-Tag1 plasmids DNA mixed with 45 μl
LipofectAmine 2000 reagent. Cells were collected for
total protein extraction 21 h after transfection. For cellu-
lar localization of SDIM1, mouse primary cortical neu-
rons were stained (or double-stained) with anti-SDIM1
(dilution1:100 v/v), anti-MAP2 (1:200 v/v dilution, Novus
Biologicals, Inc Littleton, CO), or anti-DNAJB4 (1:100 v/
v dilution, abcam, Cambridge, MA) antibodies, followed
by FITC -conjugated anti-rabbit IgG, rhodomine-conju-
gated anti-mouse IgG (for MAP2 and DNAJB4). The
nuclei were counterstained with DAPI in PBS for 5 min
and then mounted in Vectashield mounting medium
(Vector laboratories, Burlingame CA, USA). The cells
were viewed with a Zeiss Axiovert 200 M fluorescence
microscope equipped with a Zeiss AxioCam camera
(Zeiss, Midland, ON). The images were captured and
analyzed using Zeiss Axiovision 3.1 software.
Antibody production and purification
Custom polyclonal antibody (GenScprit, Piscataway, NJ)
was produced using synthetic peptide N’-
LGSPLSLWSIKTPS. The immune serum was purified by
immunoaffinity purification using recombinant GST-
SDIM1 fusion protein. Briefly, purified GST-SDIM1
fusion protein was separated by SDS-PAGE and electro-
blotted onto a nitrocellulose membrane. The Ponceau
stained membrane portion containing the SDIM1 anti-
gen was excised and subjected to a Western blotting
procedure using 2 mL original crude serum. The bound
antigen-specific antibody was eluted with 0.1 M Gly-
cine-HCl buffer, pH 2.7. The eluted antibody was neu-
tralized by adding 1/10 volume of 1 M Tris, pH 8.5,
concentrated using Amicon Ultra-15 Centrifugal Filter
Device (Millipore, Fisher Scientific, Ottawa, ON).
Protein extraction, Western blotting and co-
immunoprecipitation
Recombinant GST-SDIM1 fusion protein was purified
from Rosetta cells using a glutathione column according
to the manufacturer’s instruction (GE Healthcare, Baie
d’Urfe Quebec). Mouse tissuesw e r ef r o z e ni nl i q u i d
nitrogen and homogenized in RIPA buffer in an electronic
homogenizer and then kept on ice for 45 min. The sam-
p l e sw e r ec e n t r i f u g e da t1 4 , 0 0 0x gf o r1 0m i na t4 ° Ct o
collect the supernatant for total cellular proteins. For total
p r o t e i ne x t r a c t i o nf r o mc u l t u red cells, cells were trypsi-
nized and collected by centrifugation. They were washed
twice with PBS and lysed with RIPA buffer containing 1X
protease Inhibitor cocktail (Roche Diagnostics, Indianapo-
lis, IN). The lysate was vortexed and incubated on ice for
15 min, followed by sonication for 30 sec. In some cases
the total cellular protein was freeze-dried and reconsti-
tuted in PBS in order to achieve a higher concentration.
Western blotting analyses were performed as previously
described [25]. Human tissue protein blot was purchased
from BioChain Institute, Inc (Hayward, CA, USA). Each
lane contains 50 μg of total cellular protein. The blots
were probed with the following primary antibodies: Rabbit
polyclonal, affinity-purified anti-SDIM1 (1:5000), rabbit
polyclonal anti-flag (1:1000, Rockland, Gilbertsville, PA),
mouse monoclonal anti-DNAJB4 (1:1000, Abcam, Cam-
bridge, MA), mouse monoclonal anti-EGFP (1:1000, Mili-
pore, Temecula, CA), goat polyclonal anti-GST (1:1000,
Amersham Phamacia Biotech, Baie d’U r f e ,Q C ) ,m o u s e
monoclonal anti-ubiquitin (1:1000) and mouse monoclo-
nal anti-b-actin (1:5000, both Sigma, Oakville, ON), and
mouse monoclonal anti-GAPDH (1:10,000 v/v, Milipore,
Temecula, CA). The antigens were detected using horse-
radish peroxidase-conjugated secondary antibodies: anti-
mouse IgG (1:5000 v/v), anti-rabbit IgG (1:5000 v/v, both
from Jackson ImmunoResearch Laboratories, Inc., West
Grove, PA) or anti-goat IgG (1:5000, Sigma, Oakville,
ON). The antigen-antibody complexes were visualized by
enhanced chemiluminescence using an ECL Plus detection
kit (Amersham Phamacia Biotech, Baie d’Urfe, QC).
For the co-immmunoprecipitation assay, flag-tagged
DNAJB4 and EGFP-tagged SDIM1 constructs were transi-
ently co-transfected into HEK-293 cells and total cellular
proteins were extracted as described above. In another
case, purified GST-SDIM1 protein was mixed with cellular
proteins extracted from HEK-293 cells transfected with
pEGFP-N1 or pSDIM1-EGFP. The immunoprecipitation
procedure was as described previously [26] and precipi-
tated complexes were boiled in protein loading buffer and
s e p a r a t e db yS D S - P A G E .T h ep r e s e n c eo fS D I M 1 ,
DNAJB4, GST-SDIM1, and SDIM1-EGFP in the complex
was revealed by Western blotting as described above.
Yeast two-hybrid screening
Human cDNA encoding the full length SDIM1 protein was
cloned into the pGBKT7 vector (Clontch, Palo Alto, CA,
USA) to generate a chimaeric open reading frame encoding
the Gal4 DNA binding domain and SDIM1 protein. This
construct was introduced into Saccharomyces cerevisiae
strain AH109. A single colony containing cells harboring
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host cells for screening a human brain cDNA expression
library constructed using the pACT2 vector (Clontech,
Palo Alto, CA, USA). The protein-protein interaction was
first screened by plating the transformants onto SD/-Trp-
Leu-His-Ade selection plates. Positive clones were then re-
screened for the presence of b-galactosidase activity to
eliminate false interactions. Library plasmids harboring
SDIM1 interacting proteins were rescued and re-intro-
duced into the pGBKT7/SDIM1-containing host cells to
further eliminate false interactions. The identity of the
cDNA encoding SDIM1-interacting protein was revealed
by DNA sequencing and database searches.
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